Program
fludarabine
Also written as “Fludarabine”, “Cyclophosphamide,Fludarabine” and “TC-D101 CAR-T”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Non-Hodgkin · Glioblastoma, led by 18 companies.
Drug pageFludarabine: every studyMany companies study it; this page follows only the 35 they lead. All 745 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Biotechits history only | 99 open or running | phase 2since Apr 5, 2026 | Mar 14, 2026 | Feb 18, 2027phase 1 · NCT07480941 |
| Hoffmann-La Rocheits history only | 60 open or running | phase 4since Jan 4, 2011 | Oct 16, 2007 | none ahead |
| Allogene Therapeuticsits history only | 32 open or running | phase 2since Dec 8, 2022 | Dec 8, 2022 | Dec 2027phase 2 · NCT06500273 |
| Hangzhou Huasai Biomedicineits history only | 22 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | Aug 30, 2027phase 1 · NCT07105176 |
| Shanghai First Song Biotechnologyits history only | 21 open or running | early phase 1since Jul 30, 2024 | Jul 30, 2024 | none ahead |
| Adicet Therapeuticsits history only | 10 open or running | phase 1since Jan 26, 2021 | Jan 26, 2021 | none ahead |
| Biotech Equity Partners Ptyits history only | 10 open or running | phase 1since Feb 20, 2008 | Feb 20, 2008 | none ahead |
| Bristol-Myers Squibbits history only | 11 open or running | phase 1since Feb 7, 2025 | Feb 7, 2025 | Mar 15, 2029phase 1 · NCT07115745 |
| Caribou Biosciencesits history only | 11 open or running | phase 1since Nov 16, 2020 | Nov 16, 2020 | none ahead |
| CARsgen Therapeuticsits history only | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| Gilead Sciencesits history only | 10 open or running | phase 1since Oct 13, 2017 | Oct 13, 2017 | none ahead |
| Johnson & Johnsonits history only | 11 open or running | phase 2since Aug 25, 2025 | Aug 25, 2025 | Apr 12, 2028phase 2 · NCT07149857 |
| Neukio Biotherapeutics (Shanghai)its history only | 11 open or running | early phase 1since Aug 19, 2025 | Aug 19, 2025 | Jan 14, 2027early phase 1 · NCT07144462 |
| Precision BioSciencesits history only | 10 open or running | phase 2since Jul 19, 2019 | Jul 19, 2019 | none ahead |
| Seah Lim M.D.its history only | 10 open or running | phase 2since Aug 29, 2012 | Aug 29, 2012 | none ahead |
| Shanghai Ming Ju Biotechnologyits history only | 11 open or running | phase 1since Feb 5, 2023 | Feb 5, 2023 | none ahead |
| Shanghai Unicar-Therapy Bio-medicine Technologyits history only | 11 open or running | phase 1since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| TCRCure Biopharmaits history only | 11 open or running | early phase 1since Nov 17, 2025 | Nov 17, 2025 | Nov 30, 2027early phase 1 · NCT07246304 |
Also a collaborator on its studies: Natera.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Oct 16, 2007.
- Feb 5, 2023Shanghai Ming Ju Biotechnology’s first study: phase 1 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNew to Shanghai Ming Ju BiotechnologyShanghai Ming Ju Biotechnology · NCT05727683 · 33 planned · China
- Jun 26, 2024Phase 2 study in Lymphoma, Large B-Cell, DiffuseAllogene Therapeutics · NCT06500273 · 250 planned · United States, Australia, Canada and more
- Jul 30, 2024Shanghai First Song Biotechnology’s first studies: 2 early phase 1 studiesNew to Shanghai First Song BiotechnologyShanghai First Song Biotechnology · NCT06532643, NCT06532630
- Feb 7, 2025Bristol-Myers Squibb’s first study: phase 1 study in Autoimmune DiseasesNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT07115745 · 125 planned · United States, Australia, Brazil and more
- Jul 8, 2025Phase 1 study in Lupus Erythematosus, SystemicAllogene Therapeutics · NCT07085104 · 66 planned · United States, Canada
- Jul 22, 2025Hangzhou Huasai Biomedicine’s first study: phase 1 study in Advanced Non-Small Cell Lung CancerNew to Hangzhou Huasai BiomedicineHangzhou Huasai Biomedicine · NCT07105176 · 12 planned · China
- Aug 19, 2025Neukio Biotherapeutics (Shanghai)’s first study: early phase 1 study in AutoimmuneNew to Neukio Biotherapeutics (Shanghai)Neukio Biotherapeutics (Shanghai) · NCT07144462 · 8 planned · China
- Aug 25, 2025Johnson & Johnson’s first study: phase 2 study in Multiple MyelomaNew to Johnson & JohnsonJohnson & Johnson · NCT07149857 · 60 planned · United States, Australia, Spain
- Nov 17, 2025TCRCure Biopharma’s first study: early phase 1 study in Small Cell Lung CarcinomaNew to TCRCure BiopharmaTCRCure Biopharma · NCT07246304 · 24 planned · China
- Mar 14, 2026Beijing Biotech’s first studies: 2 phase 1 studiesNew to Beijing BiotechBeijing Biotech · NCT07480941, NCT07492628
- Apr 5, 20264 phase 2 studiesPhase 2 reachedBeijing Biotech · NCT07523542, NCT07523529, NCT07551362 and 1 more
- Apr 18, 2026Phase 1 study in GliomaBeijing Biotech · NCT07551336 · 36 planned · China
- May 14, 20262 phase 2 studiesBeijing Biotech · NCT07598955, NCT07617805
- Sep 15, 2026Phase 1 study in Advanced NSCLCHangzhou Huasai Biomedicine · NCT07830342 · 24 planned · China
Ahead
- Jan 14, 2027Primary completion: early phase 1 study in AutoimmuneNeukio Biotherapeutics (Shanghai) · NCT07144462
- Feb 18, 2027Primary completion: phase 1 study in GlioblastomaBeijing Biotech · NCT07480941
- Mar 14, 2027Primary completion: phase 2 study in RecurrenceBeijing Biotech · NCT07617805
- Mar 14, 2027Primary completion: phase 2 study in Stomach NeoplasmsBeijing Biotech · NCT07551362
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07830342Advanced NSCLC · China | 1 | Recruiting | Hangzhou Huasai Biomedicine | Oct 2028 | 24 |
| NCT07617805Recurrence · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 42 |
| NCT07598955Thymoma · China | 2 | Recruiting | Beijing Biotech | Jun 14, 2027 | 36 |
| NCT07551362Stomach Neoplasms · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 36 |
| NCT07551349Clear-cell metastatic renal cell carcinoma · China | 2 | Recruiting | Beijing Biotech | Apr 14, 2027 | 36 |
| NCT07551336Glioma · China | 1 | Recruiting | Beijing Biotech | Apr 14, 2027 | 36 |
| NCT07523542Lupus Erythematosus, Systemic · China | 2 | Recruiting | Beijing Biotech | Mar 14, 2027 | 24 |
| NCT07523529Neoplasm Metastasis · China | 2 | Recruiting | Beijing Biotech | Apr 14, 2027 | 72 |
| NCT07492628Urinary Bladder Neoplasms · China | 1 | Recruiting | Beijing Biotech | Jun 14, 2027 | 42 |
| NCT07480941Glioblastoma · China | 1 | Recruiting | Beijing Biotech | Feb 18, 2027 | 36 |
| NCT07246304Small Cell Lung Carcinoma · China | Early 1 | Recruiting | TCRCure Biopharma | Nov 30, 2027 | 24 |
| NCT07149857Multiple Myeloma · United States, Australia, Spain | 2 | Recruiting | Johnson & Johnson | Apr 12, 2028 | 60 |
| NCT07144462Autoimmune · China | Early 1 | Recruiting | Neukio Biotherapeutics (Shanghai) | Jan 14, 2027 | 8 |
| NCT07105176Advanced Non-Small Cell Lung Cancer · China | 1 | Recruiting | Hangzhou Huasai Biomedicine | Aug 30, 2027 | 12 |
| NCT07085104Lupus Erythematosus, Systemic · United States, Canada | 1 | Recruiting | Allogene Therapeutics | Feb 2028 | 66 |
| NCT07115745Autoimmune Diseases · United States, Australia, Brazil and more | 1 | Recruiting | Bristol-Myers Squibb | Mar 15, 2029 | 125 |
| NCT06532643Lymphoma · China | Early 1 | UNKNOWN | Shanghai First Song Biotechnology | Sep 1, 2025 | 9 |
| NCT06532630B-Cell Malignancy · China | Early 1 | Recruiting | Shanghai First Song Biotechnology | Sep 1, 2025 | 9 |
| NCT06500273Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more | 2 | Recruiting | Allogene Therapeutics | Dec 2027 | 250 |
| NCT05727683Precursor Cell Lymphoblastic Leukemia-Lymphoma · China | 1 | Recruiting | Shanghai Ming Ju Biotechnology | Oct 31, 2023 | 33 |
| NCT05714345Recurrence · United States, Belgium | 2 | Terminated | Allogene Therapeutics | Feb 20, 2024 | 2 |
| NCT04825496Recurrence · China | 1 | Recruiting | Shanghai Unicar-Therapy Bio-medicine Technology | Dec 31, 2023 | 18 |
| NCT04735471Lymphoma, Follicular · United States | 1 | Terminated | Adicet Therapeutics | Feb 3, 2025 | 34 |
| NCT04637763Lymphoma, Non-Hodgkin · United States, Australia, Israel | 1 | Active, not recruiting | Caribou Biosciences | Sep 11, 2025 | 72 |
| NCT04030195Lymphoma, Non-Hodgkin · United States | 2 | Completed | Precision BioSciences | Jun 24, 2021 | 18 |
| NCT03318861Multiple Myeloma · United States | 1 | Terminated | Gilead Sciences | Dec 17, 2018 | 17 |
| NCT02876978Lung Squamous Cell Carcinoma · China | 1 | UNKNOWN | CARsgen Therapeutics | Oct 2017 | 20 |
| NCT02533401Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Venezuela | 2 | Completed | Hoffmann-La Roche | Dec 2014 | 34 |
| NCT01679041Multiple Sclerosis · United States | 2 | Terminated | Seah Lim M.D. | Nov 2013 | 1 |
| NCT01292603Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Australia, Brazil and more | 1 | Completed | Hoffmann-La Roche | May 7, 2014 | 240 |
| NCT01283386Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | Hoffmann-La Roche | Mar 16, 2016 | 26 |
| NCT01271010Leukemia, Lymphocytic, Chronic, B-Cell · Russian Federation | 4 | Terminated | Hoffmann-La Roche | May 4, 2016 | 89 |
| NCT01263704Leukemia, Lymphocytic, Chronic, B-Cell · Israel | 2 | Completed | Hoffmann-La Roche | Apr 3, 2017 | 42 |
| NCT00625430Prostatic Neoplasms · Australia | 1 | UNKNOWN | Biotech Equity Partners Pty | Dec 2012 | 18 |
| NCT00545714Leukemia, Lymphocytic, Chronic, B-Cell · Spain | 2 | Completed | Hoffmann-La Roche | May 20, 2016 | 86 |
How it is read
Names in the registry
- “Fludarabine”, 40 entries
- “Cyclophosphamide,Fludarabine”, 4 entries
- “TC-D101 CAR-T”, 1 entry
- “CD19-targeted Chimeric Antigen Receptor (CAR) T Cells”, 1 entry
- “fludarabine, rituximab, pixantrone”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 7 studies
- Multiple Myeloma, 4 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 3 studies
- Lymphoma, Non-Hodgkin, 3 studies
- Glioblastoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.